AI-generated · cited to primary sources · not investment advice · How we research
Marksans Pharma
Our verdict on Marksans Pharma isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
Q1 FY26 R&D spending was exactly 2% of consolidated revenue, aligning with the upper end of the guided range. (3 met across 3 tracked commitments)
“Moving on, we do expect the R&D expenditure to remain between, say, 1.9% to 2% on a year-on-year basis.”
Q1FY26 EBITDA margins dropped significantly to 16.1% compared to 21.7% in Q1FY25 and 20.3% for full year FY25, primarily due to ramp-up costs at the acquired facility and a one-time ECL provision. (1 missed, 4 met across 5 tracked commitments)
“So, I think in next two to three quarters, it should come back to 120-130 days.”
The U.S. order book currently stands at over $220 million, showing progress toward the $300 million target. (1 in progress across 1 tracked commitment)
“We are still targeting 300 million in a three years. ... Order book, yes.”
The company has incorporated subsidiaries in Ireland and Germany (with the first employees joining in Feb 2026) and is in the process of obtaining licenses. (2 in progress across 2 tracked commitments)
“And our operations would be full flow in the 1st Quarter of '26. But you will see results probably in the second half of '26 coming from the German market and from the European market.”
Management now reports that the Teva plant (Unit 2) is only utilized at approximately 30%, indicating a slower ramp-up than the 50% target previously set for this period. (1 revised across 1 tracked commitment)
“Our Teva plant, I would say, is basically 30%, if not less utilized.”
See the full cited Management analysis of Marksans Pharma
How durable is the business?
Operating leverage is expanding as the Unit 2 (Teva) facility ramps up, though margins were temporarily impacted by headcount additions at this site. The facility successfully passed a US FDA inspection with zero observations. (1 expanding)
“Accreditations: USFDA, UK MHRA, Australian TGA, EU and Health Canada.”
The company is aggressively expanding its product pipeline with 58 SKUs commercialized during the year and 79 more products in the pipeline. (2 expanding)
“And during the year, we managed to commercialize 58 SKUs and have about 79 more products in the pipeline.”
The US market showed robust growth of 30.6% YoY, driven by new launches in digestive and pain management, despite seasonal softness and tariff-related front-loading of inventory. (1 expanding)
“Revenue from the U.S. and North America market stood at INR327.6 crores, an increase of 30.6% on a year-on year basis”
Profitability is expanding due to operating leverage from the Teva facility and softening raw material prices, leading to a 184 bps gross margin expansion. (1 expanding)
“The gross margin expansion of 184 basis points on a year-on-year basis is attributed to softening of raw material prices, a favourable product mix and also from benefits from foreign exchange movements.”
The UK and EU formulation business grew 9.2% for the full year, with the UK region achieving its highest quarterly revenue of the year in Q4. (5 expanding)
“US & North America Rs. 412.4 cr, 16.9% YoY, 54.7% share.”
See the full cited Business Model analysis of Marksans Pharma
Where does growth come from?
Revenue from the acquired Teva facility is scaling up; while it contributed Rs. 325 Cr in FY25, it is currently trending at a run-rate of Rs. 400-500 Cr for FY26, moving toward the Rs. 1,000 Cr peak capacity target. (5 accelerating across 5 signals, 2 leading indicators)
“No, I mentioned in the next 2 to 3 years is INR 4,000 crores odd, not INR 5,000 crores... Next 2 to 3 years, yes. FY28 or FY29.”
The U.S. order book is showing strong forward momentum, with management projecting an increase to $300 million within two years, despite current geopolitical uncertainties. (1 accelerating, 2 steady across 3 signals)
“Yes. Our order book still stands at a very strong $220 million plus. We are still working towards our objective of going to the next milestone.”
The US market is accelerating, showing 35% YoY growth in FY25, driven by a strong OTC pipeline and the goal to double US store brand OTC revenue. (3 accelerating, 2 steady across 5 signals, 3 leading indicators)
“Aim to double US store brand OTC revenue”
Marksans is aggressively expanding its product pipeline with over 100 products currently in development to sustain growth momentum. (+1 more signal)
“Continued focus on R&D investments leading to a robust pipeline of new developed & pipeline products... Products in Pipeline 100+”
US revenue shows strong acceleration in the most recent quarter (16.9% YoY) compared to the 9M average, driven by seasonal demand and new product launches. (1 accelerating across 1 signal)
“The performance is despite a high single-digit price erosion in the Rx product segments.”
See the full cited Future Growth analysis of Marksans Pharma
What could break the thesis?
The Teva facility integration is progressing but slower than expected; Q4 volumes were 200 million units against a target of 400-500 million. Revenue from the plant was Rs. 325 crores for FY25, below the eventual Rs. 1,000 crore target. (5 intensifying)
“Working capital cycle ~151 days for Q3FY26”
The risk has intensified as the UK market saw 'abnormal' price erosion in the Rx (prescription) segment, which management attributes to a 'cascading effect' of US tariff uncertainties forcing competitors to offload products in the UK. Revenue in the UK/EU segment dropped to INR 203.8 crores from INR 258.2 crores previously. (1 intensifying, 4 easing, 1 high-severity)
“US & North America ₹ 412.4 cr (54.7%) | UK & Europe ₹ 258.2 cr (34.2%)”
Management reports that price erosion for Rx products has stabilized, which is a positive shift from previous quarters where it was a primary concern for margin pressure. (4 easing, 1 stable)
“Price erosion in Rx products remained in the high single-digit range.”
Integration and expansion costs (Goa facility) and higher R&D (up 66% YoY) continue to impact EBITDA margins, which fell to 17.8% in Q4. (1 stable, 1 intensifying)
“Almost 3% of your total spends are towards R&D. However, we've not seen a material escalation in growth.”
Concentration risk is intensifying due to geopolitical factors; specifically, US import tariffs on Chinese raw materials (20% tariff) are making US-based manufacturing more expensive than Indian manufacturing. (1 intensifying)
“We are paying a 20% tariffs on raw materials. So, basically, U.S. has become more expensive to manufacture in U.S. than in India.”
See the full cited Risk analysis of Marksans Pharma
Read the full thesis on Marksans Pharma
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.